Nuveen
RNAC icon

Nuveen’s Cartesian Therapeutics RNAC Stock Holding History

Nuveen’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Buy
63,454
+26,003
+69% +$193K ﹤0.01% 3142
2026
Q1 		$230K Buy
37,451
+12,954
+53% +$92.3K ﹤0.01% 3071
2025
Q4 		$177K Hold
24,497
– – ﹤0.01% 3164
2025
Q3 		$250K Hold
24,497
– – ﹤0.01% 3098
2025
Q2 		$255K Sell
24,497
-3,372
-12% -$35.9K ﹤0.01% 3102
2025
Q1 		$367K Sell
27,869
-44,230
-61% -$790K ﹤0.01% 2990
2024
Q4 		$1.29M Buy
72,099
+47,889
+198% +$970K ﹤0.01% 2590
2024
Q3 		$390K Sell
24,210
-10,540
-30% -$165K ﹤0.01% 3089
2024
Q2 		$939K Buy
34,750
+18,406
+113% +$439K ﹤0.01% 2757
2024
Q1 		$319K Hold
16,344
– – ﹤0.01% 3090
2023
Q4 		$338K Hold
16,344
– – ﹤0.01% 3119
2023
Q3 		$520K Sell
16,344
-6,081
-27% -$203K ﹤0.01% 2838
2023
Q2 		$753K Buy
+22,425
New +$803K ﹤0.01% 2779
2022
Q2 		– Sell
-69,021
Closed -$3.02M – 3449
2022
Q1 		$3.02M Sell
69,021
-1,149
-2% -$71.9K ﹤0.01% 2314
2021
Q4 		$6.36M Sell
70,170
-2,481
-3% -$267K ﹤0.01% 1975
2021
Q3 		$9.7M Buy
72,651
+1,015
+1% +$123K ﹤0.01% 1805
2021
Q2 		$8.98M Buy
71,636
+9,808
+16% +$1.17M ﹤0.01% 1933
2021
Q1 		$8.39M Buy
61,828
+48,422
+361% +$6.01M ﹤0.01% 1892
2020
Q4 		$1.22M Buy
13,406
+4,308
+47% +$374K ﹤0.01% 2735
2020
Q3 		$677K Buy
9,098
+49
+0.5% +$3.75K ﹤0.01% 2846
2020
Q2 		$771K Buy
+9,049
New +$820K ﹤0.01% 2730

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's RNAC Position: Q2 2026 in Review

Nuveen increased its Cartesian Therapeutics (RNAC) stake by 69% in Q2 2026, buying an estimated $193K and bringing the position to 63,454 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Nuveen first reported a position in RNAC in Q2 2020 and has held it in 21 quarters since. The position peaked at $9.7M in Q3 2021. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Nuveen held 63,454 shares of Cartesian Therapeutics worth $661K as of Q2 2026.
  • Nuveen bought 26,003 Cartesian Therapeutics shares in Q2 2026, an estimated $193K.
  • Cartesian Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3142 holding.
  • Nuveen first reported a position in Cartesian Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Nuveen's Cartesian Therapeutics position peaked at $9.7M in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.